Stoke Therapeutics (STOK) Assets Average (2019 - 2026)

Stoke Therapeutics' Assets Average history runs 8 years deep, the most recent figure standing at $430.9 million for Q1 2026.

• In Q1 2026, Assets Average rose 27.01% year-over-year to $430.9 million; the TTM figure through Mar 2026 stood at $430.9 million (up 27.01% YoY), while the FY2025 annual figure was $345.0 million, up 38.03% from the prior year.
• Assets Average was $430.9 million for Q1 2026 at Stoke Therapeutics, up from $389.3 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $430.9 million in Q1 2026 to a low of $216.8 million in Q1 2024.
• Historically, Assets Average has averaged $302.8 million across 5 years, with a median of $282.4 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Assets Average decreased 19.4% in 2024, then jumped 56.49% in 2025.
• A 5-year view of Assets Average shows it stood at $266.8 million in 2022, then fell by 12.27% to $234.1 million in 2023, then gained by 20.64% to $282.4 million in 2024, then jumped by 37.85% to $389.3 million in 2025, then grew by 10.66% to $430.9 million in 2026.
• The last three Assets Average figures came in at $430.9 million (Q1 2026), $389.3 million (Q4 2025), and $372.4 million (Q3 2025), per Business Quant data.